TrialDrug design, development and therapy2021

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.

Hui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.